C12N 2760/10022
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2760/10022 (New viral proteins or individual genes, new structural or functional aspects of) appears on 43 US grants and 79 published applications in this corpus.
Search patents in C12N- Granted patents
- 43
- Published applications
- 79
- Assignees
- 51
- Inventors
- 162
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 1 |
| 2004 | 1 | 0 |
| 2005 | 1 | 3 |
| 2006 | 2 | 5 |
| 2007 | 3 | 1 |
| 2008 | 2 | 3 |
| 2009 | 3 | 3 |
| 2010 | 1 | 4 |
| 2011 | 1 | 2 |
| 2012 | 0 | 4 |
| 2013 | 2 | 0 |
| 2014 | 1 | 4 |
| 2015 | 2 | 2 |
| 2016 | 2 | 2 |
| 2017 | 2 | 1 |
| 2018 | 1 | 3 |
| 2019 | 0 | 5 |
| 2020 | 1 | 4 |
| 2021 | 1 | 4 |
| 2022 | 4 | 9 |
| 2023 | 2 | 1 |
| 2024 | 5 | 4 |
| 2025 | 1 | 8 |
| 2026 | 2 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Virus particles for therapeutic purposes18 Aug 2026US 12,708,654 B2Abalos Therapeutics GmbH
- VSV chimeric vectors13 Jan 2026US 12,522,844 B2Boehringer Ingelheim International GmbH
- Recombinant rhabdovirus encoding for CCL2128 Oct 2025US 12,453,749 B2Boehringer Ingelheim International GmbH
- Recombinant rhabdovirus encoding for a CD80 extracellular domain Fc-fusion protein24 Dec 2024US 12,171,795 B2Boehringer Ingelheim International GmbH
- Lassa virus vaccine10 Dec 2024US 12,161,711 B2CureVac AG
- Vaccines and methods6 Aug 2026US 2026/0224686 A1Cambridge Enterprise Limited
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Recombinant rhabdovirus encoding for a gasdermin30 Apr 2026US 2026/0117200 A1Boehringer Ingelheim International GmbH
- Tri-segmented pichinde viruses as vaccine vectors23 Apr 2026US 2026/0109736 A1Hookipa Biotech GmbH
- Sarna delivery system, preparation method therefor and use thereof23 Apr 2026US 2026/0110000 A1Zhejiang Free Trade Zone Hongan Base Biotechnology Co., Ltd.
Most cited
By later US patents
- Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use44US 7,517,520 B2Cytos Biotechnology AG · 2009
- Method of inducing a CTL response42US 6,977,074 B2MannKind Corporation · 2005
- Retroviral hybrid vectors pseudotyped with LCMV36US 6,440,730 B1Heinrich-Pette-Institut · 2002
- Method of inducing a CTL response28US 6,994,851 B1MannKind Corporation · 2006
- Melan-A- carrier conjugates25US 7,537,767 B2Cytis Biotechnology AG · 2009